Takeda Pharmaceuticals and Protagonist Therapeutics have signed a global licensing and partnership deal for the advanced experimental blood disorder medication, Rusfertide.

Jaguar Gene Therapy has received the green light from the FDA to initiate trials on JAG201 targeting a specific genetic variant associated with Autism Spectrum Disorder and Phelan-McDermid Syndrome.

Adaptimmune Reveals FDA Approval of Afami-cel Submission for Advanced Synovial Sarcoma Treatment with Expedited Review.

Sandoz introduces Tyruko® (natalizumab), a first-of-its-kind biosimilar aimed at treating multiple sclerosis, now available in Germany.

Johnson & Johnson has filed an additional request with the FDA for authorization of its DARZALEX FASPRO formula as a therapy option for newly identified multiple myeloma cases eligible for transplant.

U.S. and Japanese authorities have approved filings for Bristol Myers Squibb's Breyanzi, aimed at treating recurrent Follicular and Mantle Cell Lymphomas.

Vertex Reveals Encouraging Outcomes from Phase 3 Trials of VX-548 for Moderate to Intense Short-Term Pain Management.

CellVax Therapeutics has received approval from the FDA for its IND submission for FK-PC101, a new individualized immunotherapy treatment for cancer.

DP Tech has revealed its selection of a developmental contender, a promising top-tier Kv1.3 blocker aimed at tackling immune disorders like IBD and AD.

EicOsis Human Health has announced the advancement of its clinical research program, beginning a Phase 1b trial to assess the safety of its experimental drug, EC5026, through increasing dosages.

EMA evaluates GSK's Arexvy, an RSV immunization, for approval to protect adults 50-59 with high risk from RSV infection.

GSK plc announced the European Commission's approval of Omjjara (momelotinib) for market launch. This daily oral drug inhibits both JAK1/JAK2 and activin A receptor type 1.